All In Biotech

Drug Trial Radar · NCT05629546

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Phase I Study of Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

33

Planned (sponsor's estimate)

Start

Nov 6, 2024

Primary completion

Feb 28, 2029

Study completion Nov 30, 2030

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Melanoma Research Alliance; Rising Tide Foundation
First posted
Nov 29, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.

Conditions

  • Advanced Melanoma
  • Metastatic Melanoma

Interventions

  • Cytokine-induced memory-like natural killer cellsBiological

    Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).

  • RelatilmabBiological

    Standard of care

  • NivolumabBiological

    Standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For treatment with cells from an autologous source: Incidence and severity of adverse eventsTime frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
  2. For treatment with cells from an allogeneic source: Incidence and severity of adverse eventsTime frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.